Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers

The normal serum CA125 half-life and distribution of the normal serum nadir CA125 value in patients with epithelial ovarian carcinoma (EOC) have not been determined yet. Among patients with EOC, 41 patients met the inclusion criteria of the present study: the patients that underwent complete cytoreductive surgery and six cycles of platinum-containing chemotherapy, and who had no recurrent disease more than five years. Serum CA125 half-life (T1/2) during primary surgery and primary chemotherapy was calculated and serum nadir CA125 level was evaluated by logarithmic-transformed serum CA125. Median value of nadir CA125 was 7 U/ml (range 3-20 U/ml), and the mean ln (serum nadir CA125) was 1.96 +/- 0.45. Mean T1/2 was 10.4 days in all patients, and T1/2 value was associated with the preoperative serum levels of CA125. Predicted slope of CA125 regression curve was also influenced by the preoperative CA125 value. The present study provides fundamental information with regard to normal half-life time and normal nadir of CA125 in EOC patients.

Ovarian cancer; CA125; Tumor marker; Half-life; Nadir

[1] Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L. et al.: “New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada”. J. Natl. Cancer. Inst. 2000, 92, 205.

[2] Jacobs I, Bast R.C. Jr.: “The CA 125 tumor-associated antigen: a review of the literature”. Hum. Reprod. 1989, 4, 1.

[3] van der Burg M.E., Lammes F.B., van Putten W.L., Stoter G.: “Ovarian cancer: the prognostic value of serum half-life of CA 125 during induction chemotherapy”. Gynecol. Oncol. 1988, 30, 307.

[4] Buller R.E., Berman M.L., Bloss J.D., Manetta A., DiSaia P.J.: “Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival”. Gynecol. Oncol., 1992, 47, 87.

[5] Yedema C.A., Kenemans P., Voorhorst F., Bon G., Schijf C., Beex L., Verstraeten A. et al.: “CA 125 half-life in ovarian cancer: a multivariate survival analysis”. Br. J. Cancer, 1993, 67, 1361.

[6] Gadducci A., Zola P., Landoni F., Maggino T., Sartori E., Bergamino T., Cristofani R.: “Serum half-life CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of multicentric Italian study”. Gynecol. Oncol., 1995, 58, 42.

[7] Gadducci A., Cosio S., Fanucchi A., Negri S., Cristofani R., Genazzani A.R.: “The predictive and prognostic value of CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma”. Gynecol. Oncol., 2004, 93, 131.

[8] Mano A., Godinho I., Falcao A.C.: “CA 125 half-life breakpoint between a “good” and “poor” prognosis in patients with ovarian cancer”. Int. J. Gynecol. Obstet., 2005, 88, 333.

[9] Riedinger J.M., Wafflart J., Ricolleau G., Eche N., Larbre H., Basuyau J.P. et al.: “CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study”. Ann. Oncol., 2006, 17, 1234.

[10] Markman M., Federico M., Liu P.Y., Hannigan E., Alberts D.: “Significance of changes in the CA-125 antigen level on overall survival in advanced ovarian cancer”. Gynecol. Oncol. ,2006, 103, 195.

[11] Canney P.A., Moore M., Wilkinson P.M., James R.D.: “Ovarian cancer antigen CA125: a prospective clinical assessment of its role as tumor marker”. Br. J. Cancer, 1984, 50, 765.

[12] Buller R.E., Berman M.L., Bloss J.D., Manetta A., DiSaia P.J.: “CA 125 regression: a model for epithelial ovarian cancer response”. Am. J. Obstet. Gynecol., 1991, 165, 360.

[13] Crowford S.M., Peace J.: “Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?” Ann. Oncol., 2005, 16, 47.

[14] Juretzka M.M., Barakat R.R., Chi D.S., Iasonos A., Dupont J., Abu-Rustum N.R. et al.: “CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy”. Gynecol. Oncol., 2007, 104, 176.

[15] Markman M., Liu P.Y., Rothenberg M.L., Monk B.J., Brady M., Alberts D.S.: “Pretreatment CA-125 and risk of relapse in advanced ovarian cancer”. J. Clin. Oncol., 2006, 24, 1454.

[16] Prat A., Parera M., Peralta S., Perez-Benavente M.A., Garcia A., Gil-Moreno A. et al.: “Nadir CA-125 concentration in the normal range as independent prognostic factor for optimally treated advanced epithelial ovarian cancer”. Ann. Oncol., 2008, 19, 327.

[17] Pauler D.K., Menon U., McIntosh M., Symecko H.L., Skates S.J., Jacobs I.J.: “Factors influencing serum CA125II levels in healthy postmenopausal woman”. Cancer Epidemiol. Biomarkers Prev., 2001, 10, 489.

[18] Peters-Engl C., Obermair A., Heinzl H., Buxbaum P., Sevelda P., Medl M.: “CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer”. Br. J. Cancer, 1999, 81, 662.

[19] Yedema C.A., Kenemans P., Thomas C.M., Massuger L.F., Wobbes T., Verstraeten R. et al.: “CA125 serum levels in the early post-operative period do not reflect tumor reduction obtained by cytoreductive surgery”. Eur. J. Cancer, 1993, 29, 966.

[20] Riedinger J.M., Eche N., Basuyau J.P., Dalifard I., Hacene K., Pichon M.F.: “Prognostic value of serum CA bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study”. Gynecol. Oncol., 2008, 109, 194.

[21] Tsuda H., Hashiguchi Y., Nakata S., Deguchi M., Negoro S., Ishiko O., Yamamoto K.: “The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer”. Int. J. Gynecol. Cancer, 2001, 12, 435.

[22] Guppy A.E., Rustin G.J.S.: “CA125 response: can it replace the traditional response criteria in ovarian cancer?”. Oncologist 2002, 7, 437.

[23] Alagoz T., Buller R.E., Berman M., Anderson B., Manetta A., DiSaia P.: “What is a normal CA125 level?”. Gynecol. Oncol., 1994, 53, 93.

[24] Santillan A., Garg R., Zahurak M.L., Gardner G.J., Giuntoli R.L. 2nd, Armstrong D.K., Bristow R.E.: “Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range”. J. Clin. Oncol., 2005. 23, 9338.